(ROIV) – Company Press Releases
-
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma
-
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
-
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
-
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
-
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
-
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
-
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
-
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
-
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
-
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
-
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
-
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
-
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
-
Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer
-
Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific
-
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
-
Roivant Announces Completion of Redemption of its Outstanding Warrants
-
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
-
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
-
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
-
Roivant Announces Redemption of Outstanding Warrants
-
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovator
-
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
-
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
-
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
-
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
-
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Co
-
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
-
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
-
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
-
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
-
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
-
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
-
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
-
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
-
Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
-
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
-
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
-
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
-
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
-
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
-
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
-
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
-
Roivant Sciences Announces Change to its Board of Directors
-
Roivant Sciences Announces Change to its Board of Directors
-
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
-
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
-
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
-
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
-
Roivant Sciences Announces Proposed Public Offering of Common Shares
Back to ROIV Stock Lookup
